Holen Sie sich die Stockscreener-App
0.8166
5.64%
0.0436
Handel nachbörslich:
.84
0.0234
+2.87%
Schlusskurs vom Vortag:
$0.773
Offen:
$0.82
24-Stunden-Volumen:
1.39M
Relative Volume:
1.94
Marktkapitalisierung:
$36.47M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-35.58M
KGV:
-0.3082
EPS:
-2.65
Netto-Cashflow:
$-42.82M
1W Leistung:
+16.66%
1M Leistung:
-27.73%
6M Leistung:
-45.56%
1J Leistung:
-30.21%
1-Tages-Spanne:
$0.8082
$0.8581
1-Wochen-Bereich:
$0.6801
$0.8581
52-Wochen-Spanne:
$0.6573
$3.02
Iterum Therapeutics Plc Stock (ITRM) Company Profile
Firmenname
Iterum Therapeutics Plc
Sektor
Branche
Telefon
(872) 225-6077
Adresse
3 DUBLIN LANDINGS, DUBLIN 1
Vergleichen Sie ITRM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ITRM
Iterum Therapeutics Plc
|
0.8166 | 31.89M | 0 | -35.58M | -42.82M | -2.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Iterum Therapeutics Plc Stock (ITRM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-05-28 | Hochstufung | Gabelli & Co | Sell → Hold |
| 2021-03-15 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-06-02 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-01-21 | Herabstufung | Gabelli & Co | Buy → Sell |
| 2019-12-11 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2019-06-21 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Iterum Therapeutics Plc Aktie (ITRM) Neueste Nachrichten
Using data filters to optimize entry into Iterum Therapeutics plcMarket Risk Analysis & Smart Allocation Stock Reports - Newser
Will Iterum Therapeutics plc continue its uptrendLong Setup & Safe Capital Growth Stock Tips - Newser
Iterum Therapeutics plc stock trend outlook and recovery path2025 Retail Activity & Technical Buy Zone Confirmations - Newser
Analyzing Iterum Therapeutics plc with multi timeframe chartsGap Down & Weekly Top Performers Watchlists - Newser
Chart based exit strategy for Iterum Therapeutics plc2025 Breakouts & Breakdowns & Real-Time Market Sentiment Alerts - Newser
Price momentum metrics for Iterum Therapeutics plc explainedJuly 2025 Market Mood & Risk Controlled Daily Trade Plans - Newser
What’s next for Iterum Therapeutics plc stock priceLow Risk Stock Trade Opportunity Analysis - Newser
What institutional flow reveals about Iterum Therapeutics plcPattern Recognition Based Market Move Prediction - Newser
Using economic indicators to assess Iterum Therapeutics plc potentialStock Market Watch with Smart Filters - Newser
Advanced analytics toolkit walkthrough for Iterum Therapeutics plcSmart Trend Analysis With Buy Point Cues - Newser
Iterum therapeutics (ITRM) director Dunne buys $10,854 in shares - Investing.com
Iterum therapeutics (ITRM) director Dunne buys $10,854 in shares By Investing.com - Investing.com Australia
Iterum Therapeutics Director Dunne Buys 15,000 Shares at $0.72/Share on Aug 8. - AInvest
Real time pattern detection on Iterum Therapeutics plc stockSecure Buy Strategy Based on Risk Parameters - Newser
Why Iterum Therapeutics plc stock attracts strong analyst attentionLow Drawdown Picks with Weekly Updates - Newser
Developing predictive dashboards with Iterum Therapeutics plc dataFuture Growth Stock Forecasting Strategy - Newser
Will Iterum Therapeutics plc stock recover after recent dropReal Stock Picks With Setup Verification - Newser
Using Bollinger Bands to evaluate Iterum Therapeutics plcTrade Alert System with Volume Analysis - Newser
Iterum Therapeutics plc (NASDAQ:ITRM) Q2 2025 Earnings Call Transcript - MSN
Iterum Therapeutics (NASDAQ:ITRM) Downgraded by Wall Street Zen to “Sell” - Defense World
Iterum Therapeutics PLC (NASDAQ:ITRM) Short Interest Up 54.6% in July - Defense World
ITRM Reports Results - AOL.com
ITRM Reports Results - The Motley Fool
Iterum Therapeutics PLC reports results for the quarter ended June 30Earnings Summary - TradingView
Iterum Therapeutics (ITRM) Financial Outlook for 2025 - GuruFocus
Iterum Therapeutics plc SEC 10-Q Report - TradingView
Iterum Therapeutics reports Q2 results, launches ORLYNVAH, extends cash runway to 2026. - AInvest
Iterum Therapeutics to Launch ORLYNVAH™ for Uncomplicated UTIs in August 2025, Reports Q2 Financial Results - Quiver Quantitative
Iterum Therapeutics reports Q2 revenue, cash runway into 2026, ORLYNVAH launch in August. - AInvest
Iterum Earnings Show $13M Cash as Revolutionary UTI Antibiotic ORLYNVAH Readies for Historic Launch - Stock Titan
Iterum Therapeutics (NASDAQ:ITRM) Shares Down 2.5% – Here’s Why - Defense World
Iterum Therapeutics Q2 Earnings Preview: Analysts Expect EPS of $-0.13 - AInvest
How to forecast Iterum Therapeutics plc trends using time seriesBull Market Summary and Recovery Outlook - Newser
What makes Iterum Therapeutics plc stock price move sharplyFree Accurate Technical Trend Reversal Picks - Newser
Exit strategy if you’re trapped in Iterum Therapeutics plcWealth Accumulation Outlook for Safe Investors - Newser
Is Iterum Therapeutics plc showing signs of accumulationHigh Yield Watchlist with Filtered Picks - Newser
How volatile is Iterum Therapeutics plc stock compared to the marketAchieve rapid financial growth with expert help - Jammu Links News
What are the technical indicators suggesting about Iterum Therapeutics plcTremendous portfolio expansion - Jammu Links News
What is the dividend policy of Iterum Therapeutics plc stockTremendous financial leverage - Jammu Links News
Is Iterum Therapeutics plc a growth stock or a value stockBreakneck growth rates - Jammu Links News
What drives Iterum Therapeutics plc stock priceAchieve consistent profits with smart trading - Jammu Links News
What is the risk reward ratio of investing in Iterum Therapeutics plc stockGet timely advice on market trends - Jammu Links News
What catalysts could drive Iterum Therapeutics plc stock higher in 2025Access high-yield investment alerts now - Jammu Links News
What institutional investors are buying Iterum Therapeutics plc stockAchieve consistent profits with disciplined trading - Jammu Links News
Finanzdaten der Iterum Therapeutics Plc-Aktie (ITRM)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):